Age Related Macular Degeneration News and Research

RSS

RPB grants $500,000 to accelerate treatments for Retinitis Pigmentosa

Research to Prevent Blindness (RPB), the leading eye research foundation, is providing $500,000 to accelerate the development of treatments for Retinitis Pigmentosa (RP) -- a family of retinal diseases that progressively create extreme tunnel vision, loss of night vision and leave affected patients legally blind by the age of 40.

5 Jun 2014

Diverse group of researchers to address eye healthcare problems of the 21st century

For an individual the loss of sight is estimated by the RNIB to have a financial impact of -20k per year and the annual cost to the UK economy is around -6.5 billion in terms of direct healthcare costs and other costs such as unpaid carers and loss of employment.

3 Jun 2014

Study shows high BP drugs may raise likelihood of age-related macular degeneration

There may be a connection between taking vasodilators and developing early-stage age-related macular degeneration (AMD), the leading cause of vision loss and blindness among Americans who are age 65 and older, according to a study published online in Ophthalmology, the journal of the American Academy of Ophthalmology.

29 May 2014

Viewpoints: Political stand-off on insurance industry safeguards; VA's problems may lie in how government works

The Obama administration calls it an adjustment, Republicans call it a bailout and insurance companies call it the one thing that might keep them from raising rates and angering policyholders.

28 May 2014

Optegra top tips for healthy eyes this hayfever season

This year's hayfever season is upon us: the temperatures and pollen count start to rise, noses are beginning to run and eyes are starting to itch.

20 May 2014

DNA-directed RNA interference and hepatitis C: an interview with Carl Stubbings, Chief Business Officer, Benitec Biopharma

RNA interference (RNAi) is a naturally occurring process, which cells can use to silence, or ‘turn off’ unwanted genes.

From Quest Diagnostics 19 May 2014

Monthly injections to counteract AMD may not be necessary, say researchers

Researchers have found that, contrary to prvious clinical trial findings, monthly injections to counteract age-related macular degeneration (AMD) may not be necessary.

7 May 2014

Genetic biomarkers of ranibizumab response remain elusive in Koreans with AMD

Researchers have failed to find a significant genotypic effect on ranibizumab treatment response in Korean patients with neovascular age-related macular degeneration.

1 May 2014

Daily multivitamin offers modest protection against cataracts

Long-term daily use of multivitamins could help to reduce the risk of cataracts, but has no effect on the risk of visually significant age-related macular degeneration, suggests research.

1 May 2014

Genetic susceptibility, dietary antioxidants combine to reduce AMD risk

Dietary intake of antioxidants is associated with a reduced risk of developing early age-related macular degeneration in people at high genetic risk of the condition, pooled analysis of two studies suggests.

1 May 2014

Single treatment for AMD 'unlikely'

Age-related macular degeneration does not follow the same disease course from one patient to another, conclude researchers who suggest that phenotyping may be important before initiating a therapeutic trial.

1 May 2014

Early gene therapy could improve choroideremia prognosis

Retinal gene therapy could prevent loss of vision in patients with choroideremia and other retinal diseases, show the results of a phase I/II study.

30 Apr 2014

Kala Pharmaceuticals completes $22.5 million Series B financing

Kala Pharmaceuticals, Inc., a leading developer of innovative ophthalmic products based on the company's proprietary Mucus Penetrating Particle (MPP) platform technology, today announced it has completed a $22.5 million Series B financing.

23 Apr 2014

Iconic Therapeutics completes $20 million Series B-1 equity financing

Iconic Therapeutics, Inc., a biotechnology company focused on developing therapeutics for serious eye disorders, announced today that it has successfully completed a $20 million Series B-1 equity financing from new investors MPM Capital, Lundbeckfond Ventures, and H.I.G. BioVentures.

16 Apr 2014

Medicare doctor payment data reveals much about health system

The trove of data has the potential to reveal faults in drug pricing, potential fraud and could help regulators and consumers track medical spending -- but could take years to sort out.

15 Apr 2014

Researchers receive President of Ireland Young Researcher Award from Science Foundation Ireland

President of Ireland, Michael D. Higgins, has today received three recipients of the Science Foundation Ireland, President of Ireland Young Researcher Award (PIYRA) at áras an Uachtaráin.

4 Apr 2014

Study: Daily dietary supplements not associated with reduced risk for CVD in elderly

Daily dietary supplements of omega-3 polyunsaturated fatty acids (also found in fish) or lutein and zeaxanthin (nutrients found in green leafy vegetables) were not associated with reduced risk for cardiovascular disease (CVD) in elderly patients with the eye disease age-related macular degeneration.

19 Mar 2014

Ohr Pharmaceutical partners with CSHL to develop trodusquemine and related analogs

Ohr Pharmaceutical, a pharmaceutical company focused on the development of novel therapeutics for large unmet medical needs, and leading global cancer research center Cold Spring Harbor Laboratory (CSHL) today announced the establishment of DepYmed Inc., a new joint venture to develop trodusquemine and related analogs.

6 Mar 2014

Omeros submits investigational new drug to initiate OMS721 Phase 2 clinical program

Omeros Corporation today announced that it has submitted to the U.S. Food and Drug Administration (FDA) an investigational new drug (IND) application to initiate the Phase 2 clinical program for OMS721, the company's lead human monoclonal antibody targeting mannan-binding lectin‑associated serine protease-2 (MASP-2), the key regulator of the lectin pathway of the immune system.

4 Mar 2014

Acucela completes patient enrollment in Phase 2b/3 clinical trial of emixustat hydrochloride

Acucela Inc., a clinical-stage biotechnology company that specializes in discovering and developing novel therapeutics to treat and slow the progression of sight-threatening ophthalmic diseases, today announced that it has completed enrollment in its ongoing Phase 2b/3 clinical trial investigating emixustat in subjects with geographic atrophy (GA) associated with dry age-related macular degeneration (AMD).

4 Mar 2014

Age Related Macular Degeneration News and Research

RPB grants $500,000 to accelerate treatments for Retinitis Pigmentosa

Diverse group of researchers to address eye healthcare problems of the 21st century

Study shows high BP drugs may raise likelihood of age-related macular degeneration

Viewpoints: Political stand-off on insurance industry safeguards; VA's problems may lie in how government works

Optegra top tips for healthy eyes this hayfever season

DNA-directed RNA interference and hepatitis C: an interview with Carl Stubbings, Chief Business Officer, Benitec Biopharma

Monthly injections to counteract AMD may not be necessary, say researchers

Genetic biomarkers of ranibizumab response remain elusive in Koreans with AMD

Daily multivitamin offers modest protection against cataracts

Genetic susceptibility, dietary antioxidants combine to reduce AMD risk

Single treatment for AMD 'unlikely'

Early gene therapy could improve choroideremia prognosis

Kala Pharmaceuticals completes $22.5 million Series B financing

Iconic Therapeutics completes $20 million Series B-1 equity financing

Medicare doctor payment data reveals much about health system

Researchers receive President of Ireland Young Researcher Award from Science Foundation Ireland

Study: Daily dietary supplements not associated with reduced risk for CVD in elderly

Ohr Pharmaceutical partners with CSHL to develop trodusquemine and related analogs

Omeros submits investigational new drug to initiate OMS721 Phase 2 clinical program

Acucela completes patient enrollment in Phase 2b/3 clinical trial of emixustat hydrochloride

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News